ClosetMaid®, the industry leader in home storage and organization, has launched KidSpace™, a new collection of kid-tested and approved juvenile storage furniture. Comprised of 10 laminate storage items and a variety of compatible fabric drawers and wire frame fabric bins, this new line is attractive, durable, functional, safe and kid-friendly. Designed to be affordable and gender-neutral to look good anywhere in the home, KidSpace helps kids take a more active part in getting and staying organized. The entire product line ranges in price from $7.99 to $69.99 and will be available for purchase on www.closetmaid.com, popular online retailers and at select stores.
“Considering $22 billion is spent annually on toys in the USA, we created KidSpace to help keep them all organized,” said Scott Davis, vice president of product development and marketing, ClosetMaid. “Our research showed most storage products on the market classified as Juvenile/Kids were general items like bookcases and soft storage, so we wanted to take it a step further to offer something more to consumers.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8094351-closetmaid-kidspace-storage-furniture/
In new research from U by Kotex®, three in five women surveyed stated it is more difficult to exercise during their period and the majority reported opting for less challenging workouts.
U by Kotex® is hoping to rid barriers with the launch of its latest innovation – U by Kotex® FITNESS. To meet the needs of people experiencing a period, the brand is introducing three new product offerings, including:
• NEW U by Kotex Fitness Tampons with a plastic FITPAK* so you can protect your protection. Durable, compact, and discreet, FITPAK* is designed to keep your tampons ready for use, wherever you stash them.
• NEW U by Kotex Fitness Liners have DualFlex Zones* that move with you to keep protection where you need it.
• NEW U by Kotex Fitness Ultra Thin Pads are shaped to fit and flex with your body, to stay in place so you don’t have to.
To view the multimedia release go to:
https://www.multivu.com/players/English/8073651-u-by-kotex-findyourfitness/
Today, the newly-developed Body Volume Indicator (BVI)™ was revealed as a modern day measure of body composition and weight distribution following a 10-year collaboration with Mayo Clinic experts who led extensive research on fat distribution, the importance of fat assessment and the limitations of the current standard of Body Mass Index (BMI). In conjunction with the development of BVI, BVI America LLC, a subsidiary of 3D measurement pioneer Select Research, announced the launch of the revolutionary BVI Pro tablet application, which will provide an easily accessible and affordable means for the professional community to use the new BVI measurement in everyday clinical use to assess health risks.
The potential benefits of using Body Volume as a new indicator of risks were presented on April 27 by Mayo Clinic researchers, BVI America and the University of Westminster. It draws on 10 years of rigorous research, testing and validation using several potential Body Volume indices. Now BVI, calculated as a ratio between total volume and abdominal volume, can be used as a supplement to the current measurement standard of BMI, which is based solely on height and weight. BVI is considered to be a more precise means of estimating weight distribution and the fat around the organs, which is not visible to the human eye and can lead to serious health conditions, such as diabetes and heart disease. The medical and professional community at large is invited to contribute to the continued development of BVI by downloading and using the BVI Pro tablet application with their patients and clients; anonymous data collected will be analyzed by Mayo Clinic, whose research and validation of BVI will continue.
To view the multimedia release go to:
https://www.multivu.com/players/English/8093051-bvi-america-body-volume-app-health-fitness/
Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, commemorated its 50-year anniversary by awarding $150,000 in total grants to three organizations that share its goal to improve healthcare: The American Red Cross, the National Ovarian Cancer Coalition and Autism Speaks.
At a ceremony at the company’s flagship clinical laboratory in Teterboro, NJ, the company’s chairman, president and CEO Steve Rusckowski presented Health In Your Hands grants of $50,000 to representatives from each organization. Paul Brown, M.D., founder and former CEO of Quest’s predecessor company Metropolitan Pathology Laboratory, Inc. or MetPath, established in April, 1967, was also recognized at the event.
To view the multimedia release go to:
https://www.multivu.com/players/English/8080751-quest-diagnostics-50th-anniversary/
When a life-changing diagnosis brings moments of uneasiness, a glimmer of hope can make all the difference in bringing solace. As hope comes in many forms, Extended Stay America® hotels, the nation’s largest owner operated hotelier, announced today the launch of the brand’s latest initiative in their continued support for the fight against cancer – the “Give Hope” program. A natural evolution of Extended Stay America’s partnership with the American Cancer Society, the “Give Hope” program provides a platform to raise awareness and funds for pediatric cancer research.
To view the multimedia release go to:
https://www.multivu.com/players/English/8060751-extended-stay-america-give-hope-cancer-research/
The Häagen-Dazs brand is helping to change the way ingredients are grown to better support bee populations by working hand-in-hand with its farmer suppliers. The internationally-recognized ice cream brand has installed one of the largest, privately funded pollinator habitats on the farmland of its almond supplier in California’s Central Valley. No stranger to helping the bees, the brand aims to impact additional ingredients used throughout its super-premium ice cream portfolio and positively influence sustainable agriculture practices.
The “Häagen-Dazs Loves Honey Bees” program launched in 2008, and today is expanding from research and educational funding to hands-on initiatives that will rejuvenate pollinator habitats to allow native bees to flourish. Located in Chowchilla, California, the habitat consists of six and a half miles of hedgerow and 11,000 native drought-tolerant shrubs and flowering plants, impacting 840 acres of farmland. In order to supply what pollinators need, the Häagen-Dazs brand worked with expert agronomists and the Xerces Society to maximize the impact of the habitat by choosing regional plants that are attractive to pollinators. Looking forward, the team will work to create custom habitats for more of its ingredient suppliers who depend on bees to pollinate their crops.
To view the multimedia release go to:
https://www.multivu.com/players/English/8075051-haagen-dazs-sustainable-agriculture-bees-pollinator-habitats/
New York Yankees all-time great Bernie Williams is teaming up with Boehringer Ingelheim to raise awareness of a lung disease called idiopathic pulmonary fibrosis (IPF) that his father suffered from for years before he passed away in 2001. His father, Bernabé, inspired Williams to play baseball and make it to the Major Leagues, and taught him to play guitar which has become William’s second career since retiring from baseball.
In honor of his father’s battle with IPF, Williams has joined the Breathless™ campaign to turn his family’s devastating experience with this rare lung disease into a chance to help other families. Williams hopes to educate and empower others who think they may have IPF to seek early diagnosis and treatment and is encouraging people to visit the campaign website – www.BreathlessIPF.com – and share the videos and educational content through social media channels such as Facebook and Twitter.
To view the multimedia release go to:
https://www.multivu.com/players/English/8058551-bernie-williams-ipf-breathless-campaign/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
St. Jude Children’s Research Hospital is naming the institution’s principal research tower after Donald Pinkel, M.D., whose legacy of driving progress toward advancing cures for pediatric catastrophic diseases continues at the institution today.
When St. Jude was established 55 years ago, Pinkel, the hospital’s first medical director, committed to finding cures for childhood cancer, leading to groundbreaking treatments that saved countless children’s lives. Many of these cancers were deemed incurable prior to Pinkel’s research, but his distinct approach to eradicating diseases established a model for how cancers could be treated.
To view the multimedia release go to:
https://www.multivu.com/players/English/7924752-st-jude-childrens-research-hospital-donald-pinkel-tower/
WebMD and Scripps Translational Science Institute (STSI) today announced a new investigative study designed to improve researchers’ and health care professionals’ understanding of what contributes to healthy pregnancies and positive pregnancy outcomes. The Healthy Pregnancy Study will use WebMD’s newly redesigned and enhanced Pregnancy app for iPhone. Incorporation of the Apple ResearchKit software framework will enable survey participants to eConsent, easily and anonymously answer questions, and share connected device data about their pregnancies with researchers for analysis.
“Pregnant women are one of the least studied populations in medical research,” said Dr. Eric Topol, director of STSI and editor-in-chief of Medscape. “The results of our Healthy Pregnancy Study -- on the foundation of an exceptionally popular smartphone app -- will ultimately provide expectant mothers, researchers, and health care professionals with new medical insights to avoid complications during pregnancy.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7579757-webmd-stsi-healthy-pregnancy-study-app/
In today’s always-on world, people are more digitally-connected than ever before – yet less connected to one another in meaningful ways. That’s why Murad®, the pioneering clinical skincare brand, is launching the EyesUp Campaign, a new initiative designed to educate people about the danger of digital-only relationships and the power of real-world human connection. Through the campaign, Murad is encouraging people around the world to go “EyesUp” and connect with one another in real life.
Renowned as the “Father of Internal Skincare,” Dr. Murad’s groundbreaking work and research over the past decade has centered on helping people cope with Cultural Stress™, or the stress of modern living. The hallmarks of Cultural Stress include digital dependency, the inability to disconnect from work, and lowered self-esteem due to increased social expectations.
To view the multimedia release go to:
https://www.multivu.com/players/English/7833456-murad-skincare-eyesup-campaign/
Today on Rare Disease Day, My Life, Our Future, a national program founded by leaders in the bleeding disorder community, including Bloodworks Northwest, the American Thrombosis and Hemostasis Network, the National Hemophilia Foundation and Bioverativ Inc., opened the largest research repository of its kind in the world to scientists. The My Life, Our Future Research Repository is a collection of genetic data and blood samples that are linked to phenotypic data from more than 5,000 people in the U.S. with hemophilia, a rare disorder that impairs the ability of one’s blood to clot. The My Life, Our Future Research Repository will allow researchers to advance the scientific understanding of the disorder, including genetic differences that affect bleeding severity and reaction to certain treatments.
To view the multimedia release go to:
https://www.multivu.com/players/English/8046151-national-hemophilia-foundation-my-life-our-future/
